Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting by Gereon Nelles et al.
ORIGINAL
Prevention of episodic migraines with topiramate: results
from a non-interventional study in a general practice setting
Gereon Nelles • Lukas Schmitt • Thomas Humbert • Veit Becker •
Petra Sandow • Karin Bornhoevd • Dirk Fritzsche • Barbara Scha¨uble •
on behalf of the TOPMATMIG-0001 investigators
Received: 16 August 2009 / Accepted: 28 September 2009 / Published online: 6 November 2009
 Springer-Verlag 2009
Abstract The majority of patients with migraine headaches
are treated in non-specialized institutions though data on
treatment outcomes are largely derived from tertiary care
centers. The current non-interventional study explores effi-
cacy and tolerability outcomes of patients with episodic
migraines receiving topiramate as preventive agent in a gen-
eral practice setting. A total of 366 patients (87% female, mean
age 41.8 ± 11.6 years) were eligible for migraine prevention
and treated with flexible dose topiramate for 6 months (core
phase), and optionally for a total of 12 months (follow-up
phase). Overall, 261 patients (77.7% of safety analysis set,
SAF) completed the core phase. Reasons for discontinuation
included adverse events (2.1%), lost to follow-up (1.8%),
other reasons (1.5%), and end of therapy (0.3%) though in the
majority of patients who discontinued no reasons were listed.
The median daily dose at endpoint was 50 mg/day (range,
25–187.5 mg/day). The median days with migraine headaches
decreased from 6.0 to 1.2 days (p \ 0.001), median pain
intensity score decreased from 17.0 to 3.2 points (p \ 0.001).
In women with reported menstruation-associated migraine,
the median number of migraine attacks decreased from 4.0 to
0.9 (p \ 0.001). Absenteeism as well as triptan use decreased
significantly, and significant improvements in activities of
daily living and quality of life were reported. The most fre-
quently reported AEs were paraesthesia (4.2%) and nausea
(3%). Results suggest that migraine prevention with topira-
mate in a general practice is generally well tolerated and
associated with a significant improvement in migraine head-
aches and related functional impairment.
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Introduction
Migraine is a common neurological disorder affecting
approximately 12 to 14% of all women and 6 to 8% of all men
in western societies [1, 2]. It is reported that 43% of women
and 18% of men suffer from migraine at some point in their
lives [3, 4]. Due to the negative impact on quality of life,
daily activity and work-related productivity, timely diag-
nosis, and effective management of the patient is important
[5–7]. Next to non-pharmacological interventions, effective
acute and preventive treatments play an important role [8].
Migraine prevention not only reduces the frequency, sever-
ity, and duration of attacks, but was shown to reduce
migraine-related socio-economic burden [9]. Pharmacolog-
ical prevention of migraine is recommended by several
professional societies if patients fulfill criteria for preventive
treatment [10]. Multiple effective drugs are available, how-
ever, they differ in the level of scientific evidence to support
their use in migraine prevention as well as in their clinical
profile. Preventive medication frequently used and recom-
mended by professional bodies include beta-blockers,
calcium channel blockers, tricyclic antidepressants, or anti-
epileptic drugs, such as valproate and topiramate [11–16].
Topiramate is a fructopyranose sulfamate with proven effi-
cacy in migraine prevention. This was demonstrated in
several randomized, controlled clinical trials [12, 13, 18].
Most commonly, treatments are used in monotherapy,
however, there is some emerging data that in certain indi-
viduals add-on therapy might be appropriate [17].
Despite considerable burden of disease and available
class I evidence, only 1 in 5 patients who fulfill the criteria
for preventive migraine therapy are treated and consider-
able underrecognition of the disease itself is reported [19].
Though general practitioners play an important role in
disease recognition and initial treatment [20], there are
only few data on patient outcomes with topiramate derived
from non-specialized centers [21]. Therefore, the present
study is designed to explore tolerability and efficacy out-
comes in outpatients treated with topiramate for migraine
prevention in a naturalistic setting.
Methods
Study design
This was a prospective, multicenter non-interventional
study carried out between February 2006 and December
2007 in Germany. Patients were followed-up during a
6 months core phase with an optional follow-up for up to
12 months in total. The decision to extend the treatment
period from 6 to 12 months was based on physicians’ and
patients’ assessments of therapy at month 6. No formal
criteria were established. Patients were evaluated at base-
line, after approximately 2, 4, 8, 12 weeks, and after
6 months with optional follow-up after 9 and 12 months.
Patients’ demographics, disease characteristics including
frequency of migraine attacks, migraine auras and associ-
ated symptoms, pain intensity, quality of life, absenteeism,
previous and currently used preventive agents, type and
frequency of intake of acute medication, other concomitant
medication, and adverse events (AEs) were recorded in the
electronic case report form (CRF). Data on frequency,
severity, and symptoms of all headaches or auras, and the
use of acute medications were based on patient’s diaries,
which were transcribed by the investigator into the
patient’s CRF. All visits were office-based exception
except for Visit 2 (2 weeks) and Visit 4 (8 weeks), which
were optional and by phone.
Patient selection
Patients were selected from 183 non-academic neurology,
anesthesiology, or general practices in Germany. Patients,
aged 18 years and older were documented if they carried a
diagnosis of episodic migraine headaches and their diag-
nosis was based on the International Headache Society
(IHS) criteria http://www.i-h-s.org/upload/ct_clas/ihc_II_
main_no_print.pdf. The patients were prospectively fol-
lowed-up for 6 and optionally for 12 months if migraine
preventive therapy was indicated based on guidelines
published by the German Neurological Society (DGN)
http://www.ehf-org.org/Documents/Germany.pdf and the
German Society for Headache (DGKM) [10]. Migraine
headache, migraine attacks, and auras were defined based
on the IHS definitions. Patients with known hypersensi-
tivity or other contraindications prohibiting topiramate
therapy were excluded from participation.
Treatment
Topiramate (Topamax Migra¨ne; Janssen-Cilag GmbH,
Germany) was recommended to be taken based on the
summary of product characteristics. Titration rate and final
dose were guided by the patient’s clinical response to to-
piramate therapy.
Concomitant therapies
Patients were allowed to take acute rescue medications,
such as analgesics, non-steroidal anti-inflammatory drugs,
triptans, ergotamine derivatives, opioids, and other rescue
medication during any phase in the study. The use of acute
rescue medication had to be recorded in the patient diary
together with disease-related information (e.g. migraine
attack information).
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Ethics
The study was conducted in accordance with the ‘‘Emp-
fehlungen zur Planung, Durchfu¨hrung und Auswertung von
Anwendungsbeobachtungen (Recommendation for the
planning, implementation and evaluation of non-interven-
tional studies with medicinal products)’’ of the BfArM
(Federal Institute for Drugs and Medical Devices) dated 12
November 1998 and the ‘‘Notice to Marketing Authorisa-
tion Holders—Pharmacovigilance Guidelines’’ issued by
the EMEA (European Agency for the Evaluation of
Medicinal Products). Janssen-Cilag has notified the BfArM
about the conduct of the study. An independent ethics
committee (Freiburg, Germany) evaluated the study pro-
tocol and granted approval for study conduct.
Outcome measures
The primary objective of the study was to explore efficacy
and tolerability outcomes of flexibly dosed topiramate in
routine clinical practice. Exploratory efficacy outcome
measures included the change in the median number of
monthly migraine attacks from baseline to the last visit of
the core phase (6 months) and to the last visit of the optional
follow-up phase (for a maximum of 12). In addition, chan-
ges in monthly migraine days, changes in frequency of
migraine attacks, changes in pain intensity score were cap-
tured; the percentage of patients with C50%, C75%, and
[90% reduction in the mean number of monthly migraine
attacks (categorical responder rates). Types and frequencies
of AEs, the dosage of topiramate in daily practice, and the
impact of migraine on activities of daily living and on the
quality of life (HIT-6TM) were analyzed. Impairment of
daily life was measured with the impairment score. The
impairment score was calculated as (days with severe
impairment 9 3) ? (days with moderate impairment 9
2) ? (days with slight impairment 9 1), normalized to
28 days. The HIT-6TM is a tool to measure the impact of
headaches on daily life. The questionnaire consists of 6
questions with a 5-point scale (‘‘never’’, ‘‘rarely’’, ‘‘some-
times’’, ‘‘very often’’, and ‘‘always’’). The sum of the total
score ranges between 36 (no impact) and 78 (severe impact).
Statistical analyses and data management
Statistics
All statistical tests were exploratory. No adjustment for
multiple testing was performed. Last observation carried
forward (LOCF) analyses were performed for treatment
effect parameters using the last available post-dose value
of the respective parameter as the endpoint of analysis.
No other imputation of data was performed. Continuous
variables were described by the total number of observa-
tions (N), minimum, maximum, mean, standard deviation
(SD), median, and interquartile range (IQR). Categorical
variables were described by the total number of patients,
and by the number and the proportion of patients for each
category. Changes from baseline were analyzed by
exploratory Wilcoxon signed rank tests (significance level:
0.05). Data regarding AEs, previous and concomitant dis-
eases, and surgical procedures were coded using Medical
Dictionary for Regulatory Activities (MedDRA) version
10.1. The incidence of AEs was computed together with its
binomial 95% confidence interval.
Data sets analyzed
Available data of all patients were listed in patient data
listings. For analysis, the following populations were
defined: a Safety population (SAF), which included all
patients for whom documentation was started and for
whom the intake of at least one dose of topiramate was
documented, and a Treatment effect population (EFF),
which included all SAF patients for whom at least one
treatment effect variable was documented after the start of
topiramate treatment. In addition, a subanalyses was stip-
ulated to compare women with menstruation-associated
migraine at baseline versus women with migraines not
associated with menstruation at baseline. An overview on
the study populations is given in Fig. 1.
N = 373 patients started 
documentation
N = 37 patients not included    
in SAF
N = 336 patients in safety population 
 (SAF) → Safety analysis 
N = 34 patients not included 
  in EFF
N = 302 patients  in 
efficacy population (EFF)
→ Efficacy analysis 
N = 75 patients with  
premature discontinuation of 
core phase 
N = 261 patients completed 
observational period
(main phase, Month 6) 
N = 78 patients with 
premature discontinuation of 
follow-up phase
N = 183 patients completed follow up 
phase, including Visit 8 (Month 12) 
Fig. 1 Flowchart showing an overview on the study population
J Headache Pain (2010) 11:33–44 35
123
Results
A total of 336 out of 373 patients evaluated received to-
piramate (SAF). In 34 patients, no post-baseline efficacy
outcomes data were documented. Based on this, the EFF-
analysis comprised 302 patients (Fig. 1). A total of 261
patients (77.7% of SAF) completed the 6 months obser-
vational period (core phase), whereas 75 patients (22.3% of
SAF) discontinued prematurely. Reasons for premature
discontinuation were: AEs (N = 7, 2.1% of SAF), lost to
follow-up (N = 6, 1.8%), other reasons (N = 5, 1.5%), and
end of therapy (N = 1, 0.3%). In the majority of patients
though, a reason for discontinuation was not obtainable. A
total of 203 patients (60.4% of SAF) had data available at
Visit 7 (Month 9) and 183 patients (54.5% of SAF) com-
pleted the 12 months.
Baseline demographics, disease characteristics,
and previous treatment
Pertinent baseline data and disease characteristics of the
302 patients treated in the core phase (ITT-analysis) are
summarized in Tables 1 and 2. As much as 29.5% of
patients reported migraine headaches with auras and in
36.8% of women menstruation-associated migraines were
reported.
In the EFF, 139 patients (46.0% of EFF) had received
migraine preventive treatment in the past (Table 3). As
much as 82.7% (N = 115) had been exposed to 1 or 2
therapeutic attempts with beta blockers and 5.0% even to 3
to 4 attempts. Antidepressants were used at least once by
43 patients (30.9% of pretreated EFF patients). As much as
37 patients (26.6%) used Ca2?-channel blockers and 23
patients (16.5%) used anticonvulsant drugs other than
topiramate at least once (Table 3). At baseline, a total of 20
patients (6.6% of 302 EFF patients) received preventive
migraine treatment other than topiramate. The treatment
with these drugs continued during the study phase. Due to
the low number of patients, no subanalyses was added.
Topiramate dose
At baseline, the majority of patients (N = 259, 85.8% of
302 EFF patients) started on the recommended daily dose
of 25 mg; 33 patients (10.9% of EFF) started with 50 mg, 6
patients (2.0%) started on 100 mg, and 3 (1.0%) patients
started on 200 mg. One patient had an initial dose of
12.5 mg/day. After 6 months of treatment (N = 261),
44.4% of patients took a total daily dose of 50 mg, 24.9%
took 100 mg/day, and 13.0% took 75 mg/d. The mean
daily dose was 58.7 ± 27.4 mg/day at endpoint.
Efficacy outcomes
Number of migraine attacks
The median (IQR) number of migraine attacks per month
declined gradually from 4.0 (3.0–6.0) at baseline to 0.9
(0.4–1.8) after 6 months of treatment (Fig. 2a). At the 12-
month visit, a further slight improvement was documented.
Table 1 Demographic data
SAF EFF
N = 336 N = 302
Gender (N, %)
Female 292 (76.9) 266 (88.1)
Male 44 (13.1) 36 (11.9)
Age (years)
Mean ± SD 41.8 ± 11.6 41.5 ± 11.4
Median (range) 42 (18, 71) 42 (18, 71)
Height (cm)
Mean ± SD 168.6 ± 7.1 168.5 ± 7.0
Median (range) 168 (150, 193) 168 (150, 193)
Weight (kg)
Mean ± SD 69.1 ± 11.6 68.6 ± 11.3
Median (range) 68 (46, 110) 67 (46, 107)
BMI (kg/m2)
Mean ± SD 24.3 ± 3.7 24.2 ± 3.6
Median (range) 23.5 (17.7, 41.3) 23.4 (17.7, 38.2)
Percentages relate to the number of patients in the respective
population
Table 2 Disease characteristics
SAF EFF
N = 336 N = 302
Age at first diagnosis of migraine (years)
N 328 295
Mean ± SD 24.1 ± 9.0 24.0 ± 8.6
Median (range) 22 (8, 53) 22 (8, 53)
Time since diagnosis (years)
N 328 295
Mean ± SD 17.5 ± 11.0 17.4 ± 10.7
Median (range) 17 (0, 52) 17 (0, 52)
Migraine associated with menstruation (women only) (N, %a)
No 183 (62.7) 167 (62.8)
Yes 107 (36.6) 98 (36.8)
Aura (N, %b)
No 234 (69.6) 213 (70.5)
Yes 102 (30.4) 89 (29.5)
a Percentages relate to the number of female patients in the respective
population
b Percentages relate to the number of patients in the respective
population
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In the overall population, the number of migraine attacks
decreased to 0.8 (0.3–2.0) at endpoint. The reduction in
migraine attacks was statistically significant compared to
baseline at all visits and for the ITT population.
Number of days with migraine
The median (IQR) number of migraine days decreased
from 6.0 (5.0–8.0) days at baseline to 1.2 (0.5–2.5) days at
month 6 (Fig. 2b). At the end of the follow-up period
(month 12), the median (IQR) for migraine days was 0.7
(0.3–1.8) and 0.9 days (0.4–2.7) in the ITT population. The
reduction in the number of migraine days was statistically
significant compared to baseline (p \ 0.001) at all visits
and for the ITT population. Six patients were identified
who had 15 or more migraine days during their baseline.
Due to the small number, no further analyses were done.
Responder rates
Migraine attacks were reduced by at least 50% in 28.1% of
patients (i.e. 85 out of 302 patients) after 2 weeks of
treatment with topiramate and by at least 75.9% at end of
core phase (6 months). Outcomes remained stable during
the follow-up phase (month 9: 80.8%, month 12: 79.2%).
Results were similar in the ITT population. Here, 76.8%
achieved at least 50% reduction in migraine attacks (Fig. 3).
A clinically relevant proportion of patients achieved
complete freedom of migraine headaches (100% reduction).
The percentage increased from 13.9% after 2 weeks to
Table 3 Frequency and type of
previous migraine prevention in
EFF population (N = 302)
Patients with preventive treatment 139 (46.0)
Number of therapeutic trials/drugs used 1–2 3–4 5–10 [10
Beta blockers 115 (82.7) 7 (5.0) 1 (0.7) 1 (0.7)
Ca2?-channel blockers 37 (26.6) 1 (0.7)
Anticonvulsants 23 (16.5)
Antidepressives 43 (30.9) 2 (1.4) 1 (0.7)
Other 14 (10.1) 3 (2.2) 1 (0.7)
Q1 to Q3 with median
mean
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Fig. 3 Responder rates for the
number of migraine attacks and
the mean number of days with
migraine. Percentages relate to
the number of patients with
documented visits. Responder
rates for days with migraine
headache are not described in
the text
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18.2%, 21.6%, and 22.1% after 4, 8, and 12 weeks. At the
two follow-up visits, the proportion of patients with 100%
reduction in migraine attacks reached approximately 21%
(month 9: 20.7%, month 12: 20.8%). The calculated LOCF
was 21.2%.
Pain intensity scores
Figure 4 illustrates the decrease in the pain intensity score
results in the course of the study period. The median (IQR)
migraine intensity score decreased in patients with
remaining migraine over time. At baseline, a score of 17.0
(12.0–24.0) points was calculated in 294 patients, declining
to 12.0 (7.5–19.4) points at week 2 (N = 257), 4.6 (2.8–
9.3) points at week 8 (N = 224), and 3.2 (1.5–6.2) points at
month 6 (N = 228). During follow-up, further decrease
was noted with the lowest value of 2.0 (1.0–5.0) points
achieved at month 12 (N = 142). The median (IQR) LOCF
was 2.6 (1.3–7.0) points (N = 298). Changes from baseline
were statistically significant (p \ 0.001) at all visits as well
as for the ITT population.
Migraine with aura
At baseline, 81 out of 302 patients (26.8%) reported migraine
with aura, 215 patients (71.2%) had no aura, and data were
missing for 6 patients (2.0%). During the course of study,
the proportion of patients with reported aura decreased.
At month 6, only 17 patients (6.5%) and at month 12, only 12
patients (6.6%) reported migraine with aura.
Migraine and menstruation
A subanalyses explored efficacy outcomes in women with
and without menstruation associated migraines. Results
are based on women’s reportings. A distinction between
menstruation related migraines (MRM) and pure menstrual
migraines (PMM) was not applied [22].
In women without MRM, the median (IQR) monthly
number of migraine attacks was 4.0 (3.0–6.0) at baseline
(N = 167). The median values decreased to 3.7 (2.0–6.0)
at week 2 (N = 163) and decreased further to 0.9 (0.4–2.0)
at month 6 (N = 147), and 0.6 (0.3–1.2) at month 12
(N = 95). The median LOCF was 0.7 (0.3–2.0; N = 167).
Changes from baseline were statistically significant
(p B 0.002) at all visits and for the ITT population.
In women with MRM, baseline migraine attack fre-
quency as well as treatment response were similar. The
median (IQR) monthly number of migraine attacks was 4.0
(3.0–6.0) at baseline (N = 96) and decreased to 2.8 (1.8–
6.0) at week 2 (N = 96), to 0.9 (0.3–1.6) at month 6
(N = 80), and 0.6 (0.0–1.5) at month 12 (N = 59). The
median LOCF was 0.8 (0.3–2.0; N = 98). Changes from
baseline were statistically significant (p B 0.024) at all
visits and for the ITT population (Table 4).
Impairment of activities in daily life
The impairment of daily life is illustrated in Fig. 5. The
median (IQR) impairment score decreased from 16.0
(12.0–23.0) points at baseline (N = 294) to 2.1 (0.7–4.7)
points at month 6 (N = 258), and further to 1.3 (0.3–3.3)
points at month 12 (N = 172). The median LOCF was 1.7
(0.3–5.3; N = 301). The changes from baseline were sta-
tistically significant (p \ 0.001) at all visits and for the ITT
population.
Absenteeism
The mean number of days decreased from 2.1 ± 2.4 days
at baseline (N = 298) to 1.2 ± 2.6 days at week 2
(N = 296), 0.3 ± 0.6 days at month 6 (N = 257), and
0.1 ± 0.3 days at month 12 (N = 172). Mean LOCF was
0.3 ± 1.0 days (N = 302). The changes from baseline
were statistically significant (p \ 0.001) at all visits and for
the LOCF.
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Intensity of migraine in patients with
remaining migraine
Intensity of other headache in patients with
remaining headache
Fig. 4 Intensity of migraine
and other headache in patients
with remaining headache.
Asterisk Intensity score = (days
with severe
headache 9 3) ? (days with
moderate
headache 9 2) ? (days with
slight headache 9 1)
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Quality of life (questionnaire HIT-6TM)
At baseline, patients started with clinically relevant
impairment as measured by HIT-6TM. The sum score
changed from 65.2 ± 4.6 (median: 65.0, IQR: 63.0–68.0;
N = 298) to 51.7 ± 8.8 at month 6 (median: 52.0, IQR:
46.0–58.0; N = 254, unknown N = 7), and to 47.5 ± 8.2
at month 12 (median: 48.0, IQR: 40.0–54.0; N = 177,
unknown N = 6). The mean LOCF was 48.8 ± 8.8
(median: 48.0, IQR: 42.0–56.0; N = 265). The changes
from baseline were statistically significant (p \ 0.001) at
all time points and for the ITT population LOCF (Fig. 6).
Therapy satisfaction (tolerability and prophylactic
efficacy)
The physicians assessed tolerability of topiramate as at
least ‘‘good’’ in over 90% of patients (i.e. 97.3% at month
12). The proportion of patients for whom tolerability was
rated ‘‘very good’’ increased during the course of the study:
48.9% (N = 133) at week 12, 51.0% (N = 133) at
month 6, and 63.4% (N = 116) at month 12. Tolerability
was considered ‘‘not satisfactory’’ for one patient at week
12 (0.4%) and for one patient at month 12 (0.5%). The
LOCF (N = 271) yielded very good tolerability for 57.2%,
good tolerability for 36.5%, satisfactory tolerability for
5.5%, and not satisfactory tolerability for 0.7% of patients.
Similarly, the physicians assessed the efficacy outcomes
of topiramate as at least ‘‘good’’ in over 85% of patients
(86.4% at week 12, 94% at month 12). Patients’ assess-
ment was very similar to the physicians’ assessment after
12 weeks of treatment and at the end of the observational
period (month 6). The LOCF yielded very good efficacy in
49.8%, good efficacy in 39.1%, satisfactory efficacy in
6.3%, and not satisfactory efficacy in 4.8% out of 271
patients.
Acute medication
During the 28 days prior to treatment with topiramate,
patients took triptans at 4.9 ± 3.4 days (median: 5 days,















Q1 to Q3 with median
mean
Fig. 5 Impairment of daily life. Asterisk Impairment score = (days
with severe impairment 9 3) ? (days with moderate impairment 9
2) ? (days with slight impairment 9 1)















Q1 to Q3 with median
mean
Fig. 6 Quality of life according to the HIT-6TM questionnaire
Table 4 Migraine associated with menstruation
Baseline Week 12 Month 6 Month 9 Month 12 LOCF
N = 302 N = 272 N = 261 N = 203 N = 183 N = 235
Patients N (%)
Women with documented visitsa 266 (88.1) 240 (88.2) 230 (88.1) 180 (88.7) 164 (89.6) 235 (100)
Women with migraine attacksb 259 (97.4) 177 (73.8) 196 (85.2) 134 (74.4) 119 (72.6) 187 (79.6)
Association with menstruationc
No 165 (63.7) 137 (77.4) 145 (74.0) 93 (69.4) 88 (73.9)
Yes 94 (36.3) 35 (19.8) 45 (23.0) 40 (29.9) 31 (26.1) 42 (22.5)d
a Percentages relate to the number of patients with documented visits
b Percentages relate to the number of women with documented visits
c Percentages relate to the number of women with migraine attacks
d Total count of women for whom migraine attacks associated with menstruation were observed for the first time after treatment with topiramate
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IQR: 3–7 days, N = 289). Other acute migraine medica-
tions were taken on average at 9.2 ± 11.5 days (median:
5 days, IQR: 3–12 days, N = 41). During the study, the
number of acute treatment days declined. At week 2, the
mean number of days with triptan treatment had dropped to
3.8 ± 4.8 days (median: 2 days, N = 286) and was further
decreased to 1.6 ± 3.8 days at month 6 (median: 1 day,
N = 254) and to 1.0 ± 2.6 days at month 12 (median:
0 days, N = 163). On average, other analgetics were used
for 1.3 ± 3.0 days at month 6 (median: 0 days; N = 248)
and 0.9 ± 1.1 days at month 12 (median: 0 days,
N = 163), while the mean sum of days of all other acute
migraine medications was 3.1 ± 5.6 days at month 6
(median: 1 day, N = 49) and 1.4 ± 0.8 days at month 12
(median: 1 day, N = 27).
Tolerability
In the course of the study, 101 AEs were reported in 46
patients (13.7% of 336 patients) (Table 5). A relationship
to treatment with topiramate (possible, or probable, or
highly probable) was reported for 64 AEs in 35 patients
(10.4%) by the treating physician, including two serious
AEs (stroke).
One serious adverse event occurred in a 35-year-old
obese woman (BMI 30.8 kg/m2) with known menstruation-
associated migraines for 10 years who suffered a cerebro-
vascular accident on 2nd January 2007. Seriousness was
based on medical condition as well as hospitalization. At
the time of admission, she was treated with topiramate for
12 weeks and experienced improvement in migraine
headache frequency as well as associated symptoms. The
patient took her last dose the day prior to her insult. The
patient had a history of radiation and chemotherapy for
Hodgkin´s disease in 1989. Based on the physician’s
assessment, the SAE was considered as being ‘‘possibly’’
related to topiramate therapy. No further cardio-vascular
risk factors were identified. The patient had not fully
recovered at the time of the conclusion of the study report.
She has been discharged to a rehabilitation center.
The second patient was a 52-year-old woman with a
history of episodic migraine for the last 20 years who
presented with weight loss. Subsequently, the patient was
diagnosed with pituitary insufficiency secondary to a cra-
niopharyngeoma and underwent microsurgical removal.
The relationship to topiramate therapy was rated as unli-
kely. No deaths occurred during the study.
As shown in Table 6, the most frequently reported
symptoms were nausea (total: N = 14, 4.2%; related:
N = 8, 2.4%), paresthesia (total: N = 10, 3.0%; related:
N = 9, 2.7%), and vomiting (N = 4, 1.2%). Adverse
events reported only in few patients were: fatigue (total and
related: N = 4, 1.2%), diarrhea (total: N = 5, 1.5%, rela-
ted: N = 4, 1.2%), and dizziness (total and related: N = 4,
1.2%). All other symptoms were reported by \3 patients.
The mean weight of the patients was stable in the course
of the study. At baseline, the mean weight of the 302
patients was 68.6 ± 11.3 kg (median: 67 kg, IQR range
60–75 kg). At the end of the follow-up period (month 12)
the mean weight of the remaining 183 patients was
68.1 ± 10.5 kg (median: 68 kg, IQR: 60–74 kg).
Discussion
In this open label study, tolerability and efficacy outcomes
of topiramate for preventive migraine therapy were
explored in 336 patients seen in private practices or
Table 5 Summary of adverse events
All patients N (%)
Number of patients treated 336
All adverse events
Number of adverse events 101
Patients with adverse events 46 (13.7)
Patients with serious adverse events 2 (0.6)
Number of deaths 0 (0.0)
Related adverse events
Number of adverse events 64
Patients with adverse events 35 (10.4)
Patients with serious adverse events 1 (0.3)
Number of deaths 0 (0.0)
Percentages relate to patients dosed
Related = possible ? probable ? likely relationship with topiramate
Table 6 Number of patients with reported adverse events (AEs)
during the whole study (safety-sample)
Total
All AEs AEs with CRa
N % N %
At least one AEb 46 13.7 35 10.4
At least one AE from the following classb
Paraesthesia 10 3.0 9 2.7
Dizziness 4 1.2 4 1.2
Diarrhea 5 1.5 4 1.2
Nausea 14 4.2 8 2.4
Fatigue 4 1.2 4 1.2
Vomiting 4 1.2 1 0.3
Listed are adverse events occurring in[3 patients in the total sample
a AEs with possible, probable, or very probable causal relationship
(CR) with topiramate as assessed by the investigator
b Multiple events possible
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ambulatory care centers. These practitioners are important
for successful management of the majority of migraine
patients who do not require pain management in a tertiary
care center. Both, tolerability and efficacy results in this
setting compare well to published data of controlled and
open label trials conducted in specialized academic insti-
tutions [12, 13, 23, 24].
In 35 patients (10.4%), at least one treatment-related AE
were reported. The most frequent AE was paresthesia in 10
patients (3.0%). In previous controlled trials, paresthesia
was also the most common topiramate-associated AE
(35%, 51%, and 49% of patients receiving topiramate
50 mg/day, 100 mg/day, or 200 mg/day, respectively [6%
on placebo]), and thus, higher compared to this study [13,
24, 25]. Incidence of paresthesias in patients treated with
topiramate, however, vary considerably across studies with
generally lower frequencies in open-label compared to
controlled studies. In a recent open label study of topirmate
in epilepsy patients, paresthesia was observed in 8.0% of
patients [26]. The other important AE of this study was
nausea (4.2%). All other symptoms of AEs (Table 6), such
as fatigue (1.2%), dizziness (1.2%), impaired attention
(0.9%), anorexia (0.9%), and weight loss (0.6%) occurred
less frequently. In a pooled analysis of randomized con-
trolled trials, similar frequencies were observed for nausea
(8.9%), fatigue (11.8%), dizziness (9.7%), and weight loss
(1.3%). Topiramate-associated AEs are mild or moderate
in severity and occur at consistently higher rates during the
titration period compared to the maintenance period of the
double-blind phase. Paresthesia, nausea fatigue, and diz-
ziness were also commonly reported AEs in a recent large
open label study of topiramate in migraine prevention [21].
The discontinuation rate during the 6 months core phase
due to AEs was low. Overall, 77.7% of all patients com-
pleted the 6 months core phase. Among 75 patients who
discontinued prematurely (22.3% of SAF), 7 patients
(2.1%) had AEs. The most frequent symptoms in these
patients were fatigue and nausea, each reported for two
patients, respectively. In almost 75% of patients the reason
for discontinuation is unknown and no further information
was obtainable. Even if all of these patients discontinued
due to adverse events, the effectiveness and retention
on treatment compares well to other open label studies
and provides additional support for the ease of use and
tolerability of topiramate in daily routine for migraine
prevention.
As much as 183 patients (54.5% of SAF) completed the
full 12-months observation and follow-up period) including
Visit 8. Treatment discontinuation due to AE in previous
controlled studies with topiramate was higher, likely due to
higher doses in those studies as well as fixed titration
schedule [25]. AE-related drop-outs were dose-dependent
in all randomized controlled trials [25, 27].
The lower incidence of commonly reported AE’s with
topiramate and AE-related discontinuation rate of this
study is likely due to the lower average daily dose of
57.8 mg topiramate in this study as well as the individu-
alized treatment approach. The 6 months follow up period
was optional and reasons for treatment continuation were
not formally assessed. The study was conducted at a time
when several treatment guidelines recommended discon-
tinuation of preventive therapy after 3–6 months [28]. This
has to be contrasted to clinical practice. In some patients,
longer treatment continuation might be beneficial. A
recently published double-blind placebo controlled study
supports this view by showing continued benefit of therapy
for 6 months to up to one year [12]. Recently published
data even suggest that approximately 50% of patients
might actually benefit from migraine prevention for more
than one year [29]. The number of patients who might
qualify for a diagnosis of chronic migraine was low,
therefore, a subanalyses of treatment response in this
patient group was not performed. Recent data suggest that
topiramate is effective in chronic migraine treatment [41].
The study population was predominantly female (87%,
SAF). Based on epidemiological data, a higher proportion
of men would be expected [2, 30]. An explanation might be
the lower rate of diagnosis in men compared to women
which is suggested by the American migraine study.
Though close to 50% of affected individuals are diagnosed,
the proportion of men with a diagnosis reaches only 30%
[31]. In addition, as shown in the American migraine
prevalence and prevention study, current or ever use of
preventive medication was more likely in women than in
men (odds ratio [OR] = 1.37, 95% confidence interval [CI]
1.27–1.48), increased with age and individuals with high
MIDAS grade (Grade IV vs. I, OR 2.35, 95% CI 2.09–
2.64) [32]. In addition, a higher rate of vocational activity
among men may result in limited interest to participate in
an open label study resulting in an artificially low number
of participants. Post-hoc analyses based on the pivotal trials
do not suggest a differential response in women or men as
another possible explanation [24].
After 6 months of treatment, patients receiving topira-
mate had less than one migraine attack per month. The
median number of migraine attacks declined from 4.0 to
0.9. The preventive treatment effect was maintained
throughout the follow-up phase. The number of migraine
days per month was also significantly reduced. Treatment
with topiramate was also associated with significant
improvements for several other migraine treatment effect
measures, such as pain intensity and consumption of
analgesics. At the end of the 6 months core phase, the
frequency of migraine attacks could be reduced by at least
50% compared to baseline for 76% of patients. The pro-
portion of patients with more than 50% migraine reduction
J Headache Pain (2010) 11:33–44 41
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reached 80% during the follow-up period. As much as 21%
of all patients were completely free of migraine attacks at
the end of the follow-up phase.
The efficacy data of this study are comparable with
those of randomized controlled trials. Brandes reported a
40% reduction in migraine frequency for daily doses of
100 mg and a 42% reduction for daily doses of 200 mg at
6 months endpoint [25]. Similar reduction rates were also
observed in other controlled trials [13]. Results from these
placebo-controlled trials, however, suggest that even total
daily doses at 50 mg might have a significant effect com-
pared to placebo or show at least incremental benefit. In
this study, topiramate was dosed between 25 and 200 mg/
day with a mean daily dose of 58.7. ± 27.7 mg, indicating
that reduction of migraine days and pain intensity can be
achieved with lower levels of topiramate.
Menstrual migraine was observed in 36% of female
migraineurs which is lower than the 50% expected based
on epidemiological data [33]. In this subgroup of women in
our study, a clinically relevant reduction of migraine
attacks after 6 months was observed. Compared to non-
menstrual migraine, menstrual migraine attacks are often
more severe, longer in duration, and have a poorer response
to analgesics. Epidemiological, pathophysiological, and
clinical evidences link estrogen to migraine headaches [34,
35]. For the preventive treatment of menstrual migraine,
there are grade B recommendations for the perimenstrual
use of transcutaneous estrogen 1.5 mg. Also, frovatriptan
2.5 mg twice daily and naratriptan 1 mg twice daily have
shown efficacy in prevention of menstrual migraine [22].
None of these agents was used in our patients. Even con-
sidering the limitations of this study by not having defined
menstruation-related migraines according to the interna-
tional headache society criteria [22], these data may sug-
gest that menstrual migraine attacks respond to preventive
treatment with topiramate. A post-hoc analyses based on a
recently published trial is supportive of this view [12].
We also observed significant improvement on measure-
ments of daily living activities and health related quality of
life. In the course of the 12-month study period, the median
impairment score decreased from 16.0 to 1.3 points and
the HIT-6TM score sum decreased from 65.0 to 48.0 points.
The improvement of functional outcome with topiramate
migraine prophylaxis is exemplified by the reduction of
days absent from work (from a median of 2.0 days per
month at baseline to 0.0 days after treatment). Similar
observations have been reported from other studies using
health-related quality of life endpoints, such as Migraine
Specific Questionnaire (MSQ) and the Medical Outcomes
Study 36-item Short-Form Health Survey (SF-36) [36]. In a
3-month prospective study of 103 migraine patients, for
example, all SF-36 items improved after patients were
started on pharmacologic migraine prophylaxis [37].
Improved health-related quality of life outcome and
vocational activities are prime objectives of preventive
migraine therapy. Preventive therapy with topiramate was
shown to be associated with significant decreases in
resource use based on pharmacy data claim analyses [9] as
well as an increased work place productivity based on
results of randomized controlled trials [38].
The observed treatment effects of an open label study
need to be interpreted with caution. Several controlled
studies have demonstrated a powerful placebo-effect in
migraine prevention [39]. In one meta-analysis of all pla-
cebo-controlled studies of propranolol for prevention of
migraine, the response rate for propranolol was 55.1% and
for placebo 14.3% [40]. A very recent meta-analysis
reported placebo responder rates of 21%. In the current
study, the extent of reduction in migraine attacks, migraine
days, maximum pain intensity, and consumption of anal-
gesics, however, is comparable to responder rates of active
substances in controlled studies. Therefore, the improved
migraine control observed in this study cannot be attributed
to a placebo effect alone.
The results of the current study further support that to-
piramate is generally well tolerated and effective in
migraine prevention when administered by non-specialized
physicians. Topiramate showed significant reduction in the
frequency of migraine attacks, migraine days, pain inten-
sity, and improvement on health-related quality of life
outcomes. These results may spur the effort to improve the
current underutilization of pharmacologic migraine pre-
vention outside tertiary or specialized care.
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